Vincent Aurentz Appointed to Board of Directors at Forward Therapeutics
Forward Therapeutics, Inc., a pioneering biopharmaceutical company specializing in the treatment of chronic inflammatory disorders, has recently welcomed Vincent Aurentz to its board of directors. With a strong background in the biopharmaceutical sector, Aurentz’s wealth of experience stems from over 35 years in strategic roles.
Expertise in Biopharmaceutical Leadership
Vincent Aurentz has held key positions at prominent companies, most notably as Executive Vice President and Chief Business Officer at Arena Pharmaceuticals. There, he was instrumental in driving corporate strategy and business development, which led to a remarkable acquisition by Pfizer valued at $6.7 billion. His contributions extended to Arena's successful spinout, Longboard Therapeutics, recently acquired for approximately $2.6 billion by Lundbeck, where he served on the board and played a vital role in its development.
Forward Therapeutics' Future Vision
Toufike Kanouni, CEO and co-founder of Forward Therapeutics, expressed enthusiasm about Aurentz's appointment. He believes that Aurentz’s deep understanding of corporate strategy will be beneficial as the company continues to progress its innovative pipeline of immune therapies. According to Kanouni, Aurentz's track record in fostering growth will help steer Forward in its mission to enhance the lives of patients suffering from immune-mediated disorders.
A Thrilling New Journey
During his introduction to the team, Aurentz shared his excitement about joining Forward Therapeutics. He highlighted the potential of the company’s novel oral immunomodulators, which aim to create a new wave of leading therapies. He believes these advancements could significantly improve treatment options for patients who currently face limited choices in managing their conditions.
About Vincent Aurentz
Vincent Aurentz has developed a strong reputation within the biopharmaceutical industry, serving on multiple boards, including Longboard Pharmaceuticals, Inc., and CorHepta Pharmaceuticals, Inc. His extensive background includes executive positions in various biotech firms and senior leadership roles at Merck KGaA/Merck Serono. Aurentz's academic credentials include a B.S. in Mathematics from Villanova University, where he was recognized with a prestigious Medallion Award for outstanding achievement in the field.
Forward Therapeutics Overview
As a next-generation biopharmaceutical company, Forward Therapeutics focuses on changing the landscape of chronic inflammatory disorder treatments through its innovative small-molecule immune therapies. Recently, the company raised $50 million in Series A funding from notable healthcare investors, including BVF, RA Capital, and OrbiMed. The funds will help accelerate their research and development efforts, aiming to bring transformative therapies to a wider patient population.
Contact Information
Toufike Kanouni
CEO and Co-founder
Forward Therapeutics, Inc.
(561) 232-2641
Frequently Asked Questions
Who is Vincent Aurentz?
Vincent Aurentz is a seasoned executive with over 35 years of experience in the biopharmaceutical industry, recently appointed to the board of Forward Therapeutics.
What is Forward Therapeutics' focus?
Forward Therapeutics is focused on developing novel immune therapies aimed at treating chronic inflammatory disorders.
What experience does Aurentz bring to Forward Therapeutics?
Aurentz has extensive strategic and leadership experience, having held significant positions at Arena Pharmaceuticals and other biotech firms.
What recent funding has Forward Therapeutics secured?
Forward Therapeutics raised $50 million in Series A funding from prominent healthcare investors to support its research initiatives.
How does Aurentz's role contribute to the company's mission?
Aurentz's strategic insights and proven growth track record are expected to enhance Forward's development of innovative therapies for patients.
